Overall Survival Data From CodeBreaK 300 for KRAS G12C-Mutated mCRC
By Filippo Pietrantonio, MD, Nataliya Uboha, MD, PhD - Last Updated: June 5, 2024Filippo Pietrantonio, MD, of IRCCS Istituto Nazionale dei Tumori, and Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health, continue their conversation with a review of the overall survival data from the phase 3 CodeBreaK 300 study.
Advertisement
This trial investigated sotorasib plus panitumumab versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer.
View their previous comments on ARMANI: Ramucirumab Plus Paclitaxel as Switch Maintenance for Advanced HER2-Negative Gastric/GEJ Cancer.
Advertisement
Related Posts
Dr. Michael Foote breaks down the CheckMate 8HW trial and supports dual immunotherapy as a first-line option in dMMR CRC.
Dr. Foote discusses the BREAKWATER trial and the impact of BRAF-targeted therapy in metastatic colorectal cancer.
Positive results from the phase 3 CABINET trial led to the treatment’s approval, which showed a median PFS of 13.8 months.
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.